Pipeline Therapeutics, Inc. (the Company) announced today that it has changed its name to Contineum Therapeutics, Inc. (Contineum). The Company chose Contineum (pronounced "Con-tin-E-um") to represent its continuous dedication to the pursuit of scientific discovery and cutting-edge solutions designed to benefit patients. Contineum is focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with high unmet need.

"Our goal is to create precision small molecules that can alter the course of clinical impairment in neurology, inflammation and immunology diseases. The Company’s recent expansion into fibrotic diseases expands the potential of our pipeline and this name change is an exciting reflection of that progress,” said Carmine Stengone, CEO of Contineum. “We are building a nimble biopharmaceutical company with multiple clinical indications, large potential market opportunities such as IPF and multiple sclerosis, and a discovery platform targeting clinically validated mechanisms like LPA1 and M1 aimed at modulating innate pathways to restore function in NI&I indications. We look forward to continuing to grow Contineum under our new moniker to develop product candidates to improve patients’ lives.”

In conjunction with the corporate name change, the Company will have a new website address: www.contineum-tx.com.

About Contineum Therapeutics

Contineum Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Contineum is focused on targeting biological pathways associated with specific clinical impairments, that the Company believes, once modulated, can demonstrably impact the course of disease. The Company has a pipeline of internally-developed programs to address multiple NI&I disorders, including PIPE-791, an LPA1 receptor antagonist, in Phase 1 for idiopathic pulmonary fibrosis and progressive multiple sclerosis, and PIPE-307, a potentially first-in-class selective inhibitor of the M1 receptor in Phase 2 for relapse-remitting multiple sclerosis and with a Phase 2 for depression planned to initiate in mid-2024. Contineum is developing PIPE-307 in collaboration with Johnson & Johnson Innovative Medicines. In addition, Contineum is advancing discovery efforts targeting other NI&I indications where the Company’s internally-discovered molecules and approach may have therapeutic potential.

Contineum is headquartered in San Diego, CA. For more information, please visit www.contineum-tx.com or engage with us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231213049616/en/